Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12622000430730
Ethics application status
Approved
Date submitted
3/03/2022
Date registered
16/03/2022
Date last updated
28/04/2024
Date data sharing statement initially provided
16/03/2022
Type of registration
Retrospectively registered

Titles & IDs
Public title
Change in health outcomes for Aboriginal children with chronic wet cough: a multi-centre implementation study
Scientific title
Change in health outcomes for Aboriginal children with chronic wet cough rationale and study protocol for a multi-centre implementation science study
Secondary ID [1] 306564 0
Nil Known
Universal Trial Number (UTN)
Trial acronym
APPLE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Protracted bacterial bronchitis 325457 0
Delayed or misdiagnosis 325458 0
bronchiectasis 325459 0
Condition category
Condition code
Respiratory 322837 322837 0 0
Other respiratory disorders / diseases
Infection 322838 322838 0 0
Other infectious diseases
Public Health 322839 322839 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention is implementation of a "strategy" to facilitate early recognition and management of chronic wet cough in First Nations children at the primary care level. The strategy has seven core components for each site. The core components of the strategy include:
1. First Nations Lead: appointed at each site to advise on all cultural components of project, ensure culturally secure operations with First Nations knowledge being privileged. A First Nations officer is available for all First Nations participants from recruitment to all participation components. Adherence is measured by a First Nations lead being appointed and employed for the duration of the study.
2. Stakeholder engagement - with healthcare providers (HCPs) in primary care and local hospitals, First Nations parents to generate buy-in and ascertain and address local barriers and facilitators to implementation. Engagement occurs with in-person focus groups and interviews for the purpose of identifying current state, barriers and facilitators to providing the strategy. Qualitative experts (content expert and First Nations cultural expert, who are research team members) will lead the interviews and focus groups. Focus groups will be scheduled for 30-60 minutes, and interviews will be scheduled for 10-30minutes, with an expected single attendance only by participants. There is no limit to the number of attendees for focus groups, but numbers are not expected to exceed 25 per group based on size of departments. Stakeholder engagement can occur during the pre-intervention period (approximately 12-months). Adherence is measured via a written, published report summarising the key findings, process map and tailored implementation of strategy for each site.
3. Training of HCPs (3-month period). Training via online modules, podcasts, in-person training. In-person (or virtual in-person) training (1-hour duration x 3 occasions) will be scheduled for relevant HCPs during preferred departmental time allocation by managers. The on-line module will be promoted to all staff throughout the intervention period. The module takes 45 minutes to complete and is only completed once. The 30-min podcast is intended for single listening and will be promoted throughout intervention period. The podcast is an additional resource, not primary form of teaching. In-person (or virtual) training is provided by a paediatric respiratory physician for doctors and/or paediatric respiratory clinician for other HCPs (e.g. physiotherapist or nurse). All trainers are part of the research team. Adherence is measured by metrics of completions at each site (electronic capture system) for online training and calculation of the percentage or proportion of HCPs trained out of the total number who could be trained at each site.
4. Practice changes: Easily accessible, clear clinical practice guidelines will be placed in each clinic (Source: CARPA manual p134, i.e., https://healthinfonet.ecu.edu.au/healthinfonet/getContent.php?linkid=592687&title=CARPA+standard+treatment+manual%3A+a+clinic+manual+for+primary+health+care+practitioners+in+remote+and+Indigenous+health+services+in+central+and+northern+Australia. Call-back option operational (ability to schedule follow-up with same clinician),i.e.(to be determined at each site as per need and coordinated with local Information technology department); Flow chart on wall in clinic to prompt clinicians (designed for study, source: supplementary File 3 of protocol); Electronic decision support, which includes pop-up reminder to ask about cough and link to cough guidelines within electronic medical records (designed during nil-intervention period if required and if feasible). Coordination will be facilitated by clinical practice manager. Adherence will be measured through record if booking option is operational and the total number of record flow chart placements in each clinic room per room available. Practice changes will be implemented anytime during the same 3-month period of the intervention, i.e., during the teaching period)
5. Educational resources for HCPs: (i)culturally secure Flipchart (developed with First Nations parents, consumer endorsed and used at Perth Children's Hospital (PCH) and Broome Regional Aboriginal Medical Service. https://www.telethonkids.org.au/globalassets/media/documents/research-topics/wet-cough-flipchart.pdf. The 10-page flip chart is written with simple language and pictures. Clinicians will use the tool to teach parents whose children suspected or at high risk of protracted bacterial bronchitis who attend primary care clinic. The flip chart explains a child's chronic wet cough and the risk of developing bronchiectasis and the need for medical care. It takes approximately 5-minutes to go through with the parent/carer.
(ii)Animated film version of flip chart. (time: 3min 12 sec; https://www.youtube.com/watch?v=822rxbYIZcU; Use will be by choice of clinician and/or family - in addition to flip chart or instead of flip chart). Adherence will be measured by record of adaptions of materials if required for each site and record of whom resources are provided to at each site.
6.Information campaign (Same 3-month period as HCP training). Note all materials currently available (https://www.telethonkids.org.au/our-research/research-topics/wet-cough/) and can be used in current version or may be adapted for each site during nil-intervention phase) i) Posters in clinic (3-6 posters per clinic in high traffic areas such as family centre, waiting room and paediatric areas) and community (where agreed within the community, e.g., day care centres, library, local town noticeboard). Posters depict child coughing +/- sports hero: Copy states: "Lil one got wet cough long time? Get 'em to clinic'. Local clinic logo, phone and website with more information listed (ii) Social media- advertising and information page. The page contains links to the Flipchart, local video clips, film, wet cough audio file and information about chronic wet cough - relevance and need for health seeking. Messenger service is offered where community can ask questions, responses by respiratory clinician researcher who has manager rights on Facebook page. Information given will only advise on the health message to seek medical help for chronic wet cough and will not involve specific medical advice. Targeting advertising will be on Facebook only, as per posters, which pop up in news feed of community using social media. We will target the location of the sites in the project and the surrounding areas (within 100km radius), and expect daily pop-ups if a local person is using Facebook during the 3-month campaign. Facebook Ads Manager will be used to post targeted advertisements - with 6 "boosted" posts from the page, which run for a 28-day cycle. All analytics for reach of post are collected via Facebook Ads Manager. pagehttps://www.facebook.com/wetcough/); (iii) Health promotion discussions i.e. “yarning”. (at playgroups x3 sessions/site, 30-minutes; day-cares x1 30-min session per daycare (~2-3 centres per site); small groups in homes (for remote communities only with <600 population) ~15 home visits for 15 minutes each. Trained health promotion officers from local clinic provides sessions. Officers trained during the nil-intervention period by clinician researcher. (half day course with theoretical and practical component on chronic wet cough recognition and management); (iv) Advertising- radio (3 x 30sec), television (1x 30sec) (optional) on local Indigenous stations (topic chronic wet cough) (v) Other information materials and booklets (optional) A5 booklet version of Flipchart (and child version) can be provided to family during yarning sessions or during consultations with child with respiratory illness./chronic wet cough in local clinic. Members of the research team will coordinate campaign in liaison with local champions/stakeholders. Adherence is measured by (i) Check posters placed as required; (ii) Facebook page live and reach and engagement of ads recorded and (iii) Record of number of yarning groups and attendees for each community.
7. Local champions within primary care system identified and mobilised to improve uptake of systems changes and provide audit and feedback to staff. One or two local champions will be identified per primary care clinics (at least one clinician champion will be recruited per clinic). Champions will be recruited during the focus group sessions by invitation from the clinical lead at each site. The champions will provide feedback of audited clinician medical record entries of children presenting with respiratory illness if clinician asked about cough presence, quality and duration and metrics of online module completions within the clinic at monthly departmental meetings during the intervention stage of the project (3-months). The feedback is expected to take no more than 5-minutes and will be collated for the local champion by the local research leader. Adherence is measured through recording and reporting the number of champions and interactions recorded at each site.

Timeline: The intervention components 1 and 2 commence prior to the implementation period to ensure appropriate tailoring for each site. This period will take approx 12-months. Once the intervention commences, core components 3-6 occur simultaneously.

Please note there are two groups in the study. Nil-intervention controls do not receive any intervention. The second group is the post-intervention group who are recruited following the 3-month intervention period. This group have been exposed to the lung health promotion campaign and clinicians have received training and practices have implemented required changes. The stakeholder engagement and appointment of a First Nations lead and adaption of the implementation for each site occurs during the nil-intervention period.





Intervention code [1] 322990 0
Early detection / Screening
Intervention code [2] 322991 0
Prevention
Intervention code [3] 322992 0
Behaviour
Comparator / control treatment
"Nil-interventions controls" (children with chronic wet cough presenting to primary care) do not receive any intervention as the health promotion and clinic intervention has not yet been implemented. The group of participants will be identified via medical record audit or local clinician knowledge of children presenting with respiratory illness, where parents report they sought help for their child's chronic wet cough anytime during the pre-intervention period. The participants will be contacted by telephone or mail, 6-12 weeks following presentation for their chronic wet cough.
The period of the historical data for the PC-QoL tool will be collected at any point during the nil-intervention period, i.e., up to 12 months prior to the intervention period, to allow time to recruit enough children to complete at least 12-PC-QoL tools.
Control group
Historical

Outcomes
Primary outcome [1] 330620 0
Paediatric cough-related Quality of Life (PC-QoL) tool
Timepoint [1] 330620 0
Once at 6-12 weeks following presentation to clinic for chronic wet cough
Primary outcome [2] 330621 0
Health seeking of parents: The number of parents seeking help at the local clinic for their child’s chronic wet cough during a six-month period pre- and post-intervention
Timepoint [2] 330621 0
Clinic record audit will be used to compare numbers in a 6-month period the year before implementing the intervention to numbers during 6-months directly after implementation. To reduce the effect of seasonal factors influencing results, the same 6-calendar months will be audited pre- and post-implementation
Secondary outcome [1] 406988 0
Clinicians’ proficiency in assessing and managing children presenting with respiratory illness will also be assessed via medical record audit of clinicians recording cough presence
Timepoint [1] 406988 0
The number of respiratory presentations during a six-month period pre- and post-intervention where clinician asked about cough presence. Clinic record audit will be used to compare numbers in a 6-month period the year before implementing the solution, to numbers during 6-months directly after implementation
Secondary outcome [2] 406989 0
Clinicians’ proficiency in assessing and managing children presenting with respiratory illness will also be assessed via medical record audit of clinicians recording cough quality (wet or dry or other)
Timepoint [2] 406989 0
The number of respiratory presentations during a six-month period pre- and post-intervention where clinician asked about cough quality. Clinic record audit will be used to compare numbers in a 6-month period the year before implementing the solution, to numbers during 6-months directly after implementation
Secondary outcome [3] 406990 0
Clinicians’ proficiency in assessing and managing children presenting with respiratory illness will also be assessed via medical record audit of clinicians recording cough duration
Timepoint [3] 406990 0
The number of respiratory presentations during a six-month period pre- and post-intervention where clinician asked about cough duration. Clinic record audit will be used to compare numbers in a 6-month period the year before implementing the solution, to numbers during 6-months directly after implementation
Secondary outcome [4] 406991 0
Clinicians’ proficiency in assessing and managing children presenting with respiratory illness will also be assessed via medical record audit of clinicians recording: correct management if suspected protracted bacterial bronchitis
Timepoint [4] 406991 0
The number of respiratory presentations during a six-month period pre- and post-intervention where clinician prescribed correct management for suspected protracted bacterial bronchitis.. Clinic record audit will be used to compare numbers in a 6-month period the year before implementing the solution, to numbers during 6-months directly after implementation
Secondary outcome [5] 406992 0
Implementation outcomes:
a) Fidelity to core components of the strategy will be assessed.
Acceptability (“the perception among implementation stakeholders that the strategy is agreeable, palatable and satisfactory”) will be assessed for health care providers (HCPs) and parents through semi-structured interviews.
Timepoint [5] 406992 0
This outcome will be measured during the final 3-months of the intervention period and 3-months after the intervention period has concluded.
Secondary outcome [6] 406993 0
Implementation outcome
b) Appropriateness (“the perceived fit of the strategy for the given practice setting”) will be assessed with the 22-item TCU Workshop Evaluation (WEVAL) form to assess the perceptions of the strategy directly after intervention and the 14-item TCU Workshop Assessment Follow-Up (WAFU) to assess changes 6-months after
Timepoint [6] 406993 0
The WECAL form will be given to attendees of the -in-person training session at the time of attendance and will occur once only. The same attendees will be provided with the WAFU form 6-months later and will be asked to complete. These forms will be completed electronically, via an emailed link sent to the participant or via a paper version if preferred by the participant.
Secondary outcome [7] 406994 0
Implementation outcome
c) Implementation cost will be addressed through an economic analysis. Costs data will be collected by (i) determining the cost of providing the new service, including staffing costs, consumables, cost of training, electronic system modifications; health promotion training and campaign costs and (ii) the extra cost for caring for a child with bronchiectasis over their lifetime for children predicted to develop bronchiectasis) (based on published data on Australian costs on bronchiectasis (Goyal et.al 2020 and Lovie-Toon et.al. 2019)
Timepoint [7] 406994 0
This will occur in the 3-month period following completion of the intervention period
Secondary outcome [8] 406995 0
Implementation outcome
d) Penetration and adoption will be assessed as i) the number of HCPs who participated in training out of the total number of HCPs, and ii) audit of medical records of respiratory presentations
Timepoint [8] 406995 0
The outcome for the number of HCPs trained will be measured at each training session and for respiratory presentations medical records as per audit via data linkage to electronic medical record discharge summaries throughout the intervention period .
Secondary outcome [9] 406996 0
Implementation outcomes: Sustainability will be addressed through focus groups and interviews with HCPs and parents in the final months of the project and feedback questionnaires for HCPs.
Timepoint [9] 406996 0
This will be conducted during the final 3-months of the intervention period and in the 3-months following conclusion of recruitment of children.

Eligibility
Key inclusion criteria
1. Parents help seeking and clinician management of chronic wet cough: Australian First Nations children aged 0-8 years who attend local primary care clinic for medical care during a 6-month period pre-intervention and the same 6-month period post-intervention.

2. Clinician management of chronic wet cough for PC-QoL tool): First Nations children who presented to primary care clinic with a chronic wet cough, aged 0-17 years, 6-12 weeks prior to recruitment.
Minimum age
0 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Parents help seeking: Non-First Nations children, First Nations children aged over eight years or who do not attend local clinic.

2.Clinician management of chronic wet cough for PC-QoL tool: Non-First Nations children or children who present outside the study period.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
N/A
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
N/A
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
There will be two groups of participants
1. Nil-intervention: Children and clinicians pre-intervention who are not exposed to any interventions.
2. Post-intervention group:Children and clinicians post-intervention who are exposed to the interventions.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Primary outcome measure: Un-paired Student T-tests used to analyse the change in PC-QoL-8 scores (normally distributed and the minimum important difference is 0.9). Single site analysis with at least 12 participants with chronic wet cough in each period will have >80% power to detect a nil-intervention (2.7) v post-intervention (4.3) difference of 1.6, alpha 0.05. Full sample (clustered) analysis with at least 5 participants per cluster (4) per period (assuming COV 0.65, ICC 0.01) will have >95% power to detect a nil-intervention (2.7) v post-intervention (4.3) difference of 1.6, alpha 0.05; at least 10 participants per cluster (4) per period will be required to have >80% power to detect a difference of 0.9 (alpha 0.05). Adjustments for multiple comparisons were not made as calculations are to provide guidance only, with final sample size being dependent on cohort sizes and diagnosis counts during observation periods; sample size calculations were carried out using PASS.

Secondary outcome measures: Chi Squared tests and 95% Wald CIs will be used for categorical data, i.e., pre-and post-intervention comparison of
(i) the percentage of children who attended clinic for chronic wet cough in pre and post 6-month periods
(ii) the percentage of respiratory presentations were doctor asks about cough presence, quality and duration
(iii) the percentage of respiratory presentations were doctor manages suspected protracted bacterial bronchitis correctly.

Significance is set to 0.05 .

Implementation outcomes will be measured as per protocol

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
10/05/2021
Date of last participant enrolment
Anticipated
27/12/2024
Actual
Date of last data collection
Anticipated
28/02/2025
Actual
Sample size
Target
140
Accrual to date
86
Final
Recruitment in Australia
Recruitment state(s)
NT,QLD,WA
Recruitment postcode(s) [1] 37023 0
6770 - Halls Creek
Recruitment postcode(s) [2] 37024 0
6770 - Tanami
Recruitment postcode(s) [3] 37025 0
6000 - Perth
Recruitment postcode(s) [4] 37026 0
4350 - North Toowoomba
Recruitment postcode(s) [5] 39816 0
0822 - Daly River
Recruitment postcode(s) [6] 42476 0
0880 - Gapuwiyak

Funding & Sponsors
Funding source category [1] 310896 0
Government body
Name [1] 310896 0
National Health Medical Research Council
Country [1] 310896 0
Australia
Primary sponsor type
Hospital
Name
Child and Adolescent Health Service
Address
15 Hospital Ave
Nedlands, WA 6009
Country
Australia
Secondary sponsor category [1] 312177 0
None
Name [1] 312177 0
Address [1] 312177 0
Country [1] 312177 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 310456 0
Western Australian Aboriginal Health Ethics Committee
Ethics committee address [1] 310456 0
Ethics committee country [1] 310456 0
Australia
Date submitted for ethics approval [1] 310456 0
14/01/2021
Approval date [1] 310456 0
02/03/2021
Ethics approval number [1] 310456 0
HREC774
Ethics committee name [2] 310458 0
Child and Adolescent Health Service Ethcis Committee
Ethics committee address [2] 310458 0
Ethics committee country [2] 310458 0
Australia
Date submitted for ethics approval [2] 310458 0
17/06/2020
Approval date [2] 310458 0
28/07/2020
Ethics approval number [2] 310458 0
RGS4136
Ethics committee name [3] 310459 0
Human research ethics committee of the Northern Territory Department of Health and Menzies School of Health Research
Ethics committee address [3] 310459 0
Ethics committee country [3] 310459 0
Australia
Date submitted for ethics approval [3] 310459 0
25/01/2021
Approval date [3] 310459 0
23/03/2021
Ethics approval number [3] 310459 0
HREC 2021-3954
Ethics committee name [4] 310460 0
University of Queensland's Human Reserach Ethics Committee
Ethics committee address [4] 310460 0
Ethics committee country [4] 310460 0
Australia
Date submitted for ethics approval [4] 310460 0
27/10/2020
Approval date [4] 310460 0
09/11/2020
Ethics approval number [4] 310460 0
2020002563

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 117734 0
A/Prof André Schultz
Address 117734 0
Department of Respiratory and Sleep Medicine
Perth Children's Hospital
15 Hospital Ave
Nedlands WA 6009
Country 117734 0
Australia
Phone 117734 0
+61 8 6456 8452
Fax 117734 0
Email 117734 0
[email protected]
Contact person for public queries
Name 117735 0
André Schultz
Address 117735 0
Department of Respiratory and Sleep Medicine
Perth Children's Hospital
15 Hospital Ave
Nedlands WA 6009
Country 117735 0
Australia
Phone 117735 0
+61 8 6456 8452
Fax 117735 0
Email 117735 0
[email protected]
Contact person for scientific queries
Name 117736 0
André Schultz
Address 117736 0
Department of Respiratory and Sleep Medicine
Perth Children's Hospital
15 Hospital Ave
Nedlands WA 6009
Country 117736 0
Australia
Phone 117736 0
+61 8 6456 8452
Fax 117736 0
Email 117736 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
database: individual participant data of published results only
When will data be available (start and end dates)?
Beginning 3 months and ending 5 years following main results publication;
Available to whom?
Researchers who provide a methodologically sound proposal with appropriate institutional and/or ethical approval as required
Available for what types of analyses?
only to achieve the aims in the approved proposal
How or where can data be obtained?
access subject to approvals by Principal Investigator [email protected]


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
15254Study protocol    To be published in BMC Pulmonary Medicine
15256Informed consent form    Provided in published protocol
15257Ethical approval    Will be provided in published protocol
15258Statistical analysis plan  [email protected] will be provided in published protocol



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseChange in health outcomes for First Nations children with chronic wet cough: rationale and study protocol for a multi-centre implementation science study.2022https://dx.doi.org/10.1186/s12890-022-02219-0
N.B. These documents automatically identified may not have been verified by the study sponsor.